|
Our International Visitors May Translate This Site To The Language Of Their
Choice. Simply Select Your Countries Flag Below.
    
     Parkinsons Disease Sign
Just Mobility
Mobility
Equipment For Mobility
Mobility AIDS
Parkinsons Disease Prognosis
Mobility Vehicles
Mobility In The Elderly
Parkinsons Tremor
Fatty Acids Could Protect Against Parkinson's
Muhammad Ali Still Fighting Parkinson's Disease
|
|
Parkinson's Patients Suing Amgen Over Drug
Parkinsons TremorInsight into the World of Parkinson’s Disease Sufferers Parkinson’s disease ..... This passage outlines some good reading particularly from a parkinson's point of view. I am happy to be in a position to include this splendid article which I feel pinpoints many of these greyer areas that are so very often overlooked.
wo participants in a discontinued clinical drug trial have sued Amgen, demanding that it resume giving them an experimental treatment for Parkinson's disease that they say helped them immensely but that the company says is ineffective and potentially dangerous.
In their lawsuit, filed yesterday in Federal District Court in Manhattan, the plaintiffs say Amgen "treated the patients as mere guinea pigs, as material to be discarded," and had violated a legal and moral obligation to continue to supply the drug.
A spokeswoman for Amgen said that the company had only started to review the complaint but typically would not comment on litigation.
The lawsuit is the latest step in a conflict that has raised questions about the obligations of drug companies to participants in clinical trials.
Early Sign For Parkinsons DiseaseParkinson's disease tends to be a very frightening disease to be diagnosed with. Knowing what it is and what the symptoms are will .....
Last year, Amgen said that a clinical trial showed that the drug - glial cell line-derived neurotrophic factor, or G.D.N.F. - was not significantly better than a placebo. It also said that some monkeys given high doses had developed brain damage. So Amgen stopped giving the drug to about four dozen people in the trials.
This article's coverage is as complete as it can be today. But you ought to always leave open the potentiality that future research might unlatch new pieces of evidence.
What do you make of this info so far? We are trying to address some of the key issues regarding parkinson's. Carry on reading as an understanding of this material could make a big difference in how you think about parkinson's.
But many of those patients wrote letters imploring Amgen to let them have the drug, insisting that it had greatly improved their condition. Some of the doctors involved in the trial also argued that the drug worked and was safe.
Parkinsons Disease InfoThis article gives the authors prospective of who is at more risk from getting the disease. From my own ..... But in February, Amgen reiterated its position, saying it would be unethical, would raise false hopes and would hinder long-term development of the product.
The two plaintiffs in the clinical trials, Robert Suthers of Greenlawn, N.Y., and Niwana Martin of Harpers Ferry, W.Va., were both treated at New York University.
Alan C. Milstein, their lawyer, said that other patients might be added to the suit but that it was more efficient to start with two plaintiffs because the goal was to get the court quickly to order Amgen to provide the drug.
Mr. Milstein, who is based in Pennsauken, N.J., represented the family of Jesse Gelsinger, a teenager who died in a gene therapy experiment at the University of Pennsylvania in 1999. That lawsuit was settled but details remain confidential.
The suit against Amgen argues that, in effect, drug companies and participants in their clinical trials enter into a contract. In this drug trial in particular, the lawsuit argues, patients had to undergo surgery so that G.D.N.F. could be delivered directly into their brains from tubes extending underneath the skin to pumps implanted in the abdomen. According to the lawsuit, Mr. Suthers suffered a stroke after his surgery and had to undergo a second brain operation to correctly position a catheter that had come loose.
The suit also says the company promised that if the drug were safe and effective, that it would continue to provide it to participants in the trial as long as it was helping them.
With the drug, Mr. Suthers has said he was routinely able to walk two miles.
Disease Parkinsons Sign SymptomBiologists say they have gained a new insight into the basic cause of Parkinson's disease that, if confirmed, could lead to a novel .....
Now, since coming off the drug, "he can't walk a block," said his wife, Elaine Suthers. "We don't want millions of dollars," she said. "We want the G.D.N.F. and we want a chance for some degree of normalcy in our life."
After your know how about the parkinson's continues to grow, you will begin to see how it fits into the overall scheme of things. Knowing how something relates to the rest of the world is important too.
|
|
